In our in vivo preclinical studies in a murine “cold” tumor model of pancreatic cancer, we showed that TGFβ-derived peptide vaccination controlled tumor growth [104], targeting immunosuppression in the TME by polarizing its cellular composition towards a more pro-inflammatory phenotype. Here, TGFB1 is linked to pancreatic neoplasm.